Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season.
https://finance.yahoo.com/news/why-anavex-life-sciences-avxl-123712037.html
Sign me up for A2-73 "Blarcamazine" 50mg twice a day for first 90 days. 1 year prescription home delivery via UPS, FED EX, US Postal or taxi.
Cant you hear me knocking.
I want to be the first home prescribed delivery of A2-73 in the USA.
Come on!
tradeherpete , Woo hoo. Thanks for your info. All good.
The WHO in Anaheim CA. 1983
The Rolling Stones some Girls . Anaheim 3 night's in arrow.
Best
A2-73 - Can't You Hear Me Knocking!
A2-73 Knocking on your front door. Mick Taylor guest & Bobby Keys on the saxophone. The good the bad and the ugly.
If my memory serves me correctly.
Folks we need to find another way to trade this company. WS has had its day but the manipulation and shorting only benefits the politically correct selected companies. SEC doesn't uphold the law. Let's find a way to trade Anavex on the block chain. Block chain is the way of the future. imo
Great information, georgejjl, as always. Thank you.
Summary of Topline Results:
Broad and Significant Effects with ANAVEX®2-73 (blarcamesine) in PDD Patients
• ANAVEX®2-73 (blarcamesine): a novel, oral, investigational sigma-1 receptor (Sig-1R / SIGMAR1) agonist with multimodal activity
• Data confirm SIGMAR1 as gene “signature” biomarker of response to ANAVEX®2-73 (blarcamesine) confirming SIGMAR1 activation as mechanism of action
• Broad and statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008) and CDR system Episodic Memory (p = 0.047), representing complex cognitive tasks with impact on quality of life such as making a choice between similar objects and remembering daily personal experiences, which are mostly impaired in both PD and AD
• Statistically significant dose-dependent (p = 0.003) improvement of CDR system Episodic Memory, which has been shown to be highly correlated (70%) with the Alzheimer’s Disease Assessment Scale–Cognitive score (ADAS-Cog; r = 0.7)
• ANAVEX®2-73 (blarcamesine) does not impair sleep and has a positive effect on REM sleep behavior disorder
• ANAVEX®2-73 (blarcamesine) was generally safe, well tolerated, and improved safety profile compared to dementia drugs associated with typical adverse effects
• These results support continued development in PDD / PD as well as currently ongoing Phase 2 and Phase 2/3 clinical studies with ANAVEX®2-73 (blarcamesine) in Rett syndrome3 and Alzheimer’s disease
• Data will be submitted to the U.S. Food and Drug Administration to seek regulatory guidance
http://www.anavex.com/wp-content/uploads/2021/04/Anavex-Presentation-April-2021-.pdf
Good luck and GOD bless,
Talk on the town say you might go solo.
Via Tijuana ~
Are the Mafia shorts back at work? I do believe so. imo
Common Reddit. Time to go to work. Time to kick some azz.
https://insiderfinancial.com/reddit-rebellion-targeting-the-short-mafia-next/180939/
hnbadger1- I believe you are correct with your comparison of value per price.
Could it be? Probably. More than likely? imo
https://insiderfinancial.com/reddit-rebellion-targeting-the-short-mafia-next/180939/
Great post, vg_future. Breaking it down. Thx
Journey of treatment has to be good....so, treating the symptoms will be equally attractive (maybe more in some cases) while the root cause is treated.
The tweet definitely looks good and is a great teaser.
To put it in the right context, if Memory loss is a symptom in Parkinson's...improving the memory (as stated by Anavex) can qualify as a symptom treatment.
If lack of sleep is a symptom for PD, improving sleep can qualify as a symptom treatment.
There could be lot of other symptoms that are treated by A2-73, but I picked the two obvious ones from layman perspective.
JMHO,
vg_future
We can read into it however we want. A2-73 best results on the market currently. imo
Their currently is nothing that helps PDD, PD patients. A2-73 will be the first. imo
Interesting read. Small molecule drugs were dominant approvals in 2018. Will it come back in 2021?
August is a banner month for drug approvals.
https://cen.acs.org/biological-chemistry/gene-editing/August-banner-month-drug-approvals/97/i34
Great post, tradeherpete. Lot's of great information. Thanks.
Spot on. Nice post, vg_future.
vg_future, posts.
"Some of the questions on this board are an excellent reason why some of these Armchair CEOs on this board can never ever run a company. Having an expert in the company is for a purpose...targeted to accomplish some specific things of significance and hit key milestones in the business plan....not for CCs. Putting all these specialists on the conference call is a perfect recipe for disaster.
Posters who find this strange will still be wondering even after Anavex hits major milestones and becomes a multi-billion dollar company".
A little fun for those that need to know. With special guest.
Saturday Night Special. Via Tijuana ~~
Also, I'm aware that we have the poison pill in place. Additional shares maybe needed for support. Not sure. Just my thoughts. GL
tredenwater2 - Yes, I also believe the results are good. My thoughts are Dr. Missling wanting to put this new share proposal on the table to help defend against the circling wolves that will want to acquire AVXL when stellar results are reported. Hence current manipulated pps take down.
Anavex - A2-73 Leader in the CNS biotech space. Stellar results and reviews to date. All the makings of a new block buster drug. Remember. No brain bleeding here. imo.
Many thanks to you, georgejjl. Please keep up your great posting. It's a big help for us in the industrial infrastructure world that don't know a lot of the medical details. We have learned a lot over the past years about CNS disease thanks to you and several great posters on this board. We believe AVXL has the goods and will soon find out. Best and have a great weekend.
Hey Bourbon. Right. George has a lot of great detail information in Anavex that helps folks like me in the infrastructure world. I'm an investor. Plus I need 2-73 for several CNS problems. Have a great weekend. Go with x22.
Nice post. This should be a $100.00 stock with what we know to date. imo
ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome.
https://www.anavex.com/anavex-life-sciences-announces-anavex2-73-blarcamesine-meets-primary-and-secondary-endpoints-in-placebo-controlled-u-s-phase-2-clinical-trial-for-the-treatment-of-adult-patients-with-rett-syn/
Where does this market cap go when new shares in this merger are added? Currently 3.8 Million. Thanks
This week has past me so slowly. Maybe I'll take something to help me, or just take 2-73. stay.
Perfect storm for instys. Piss off the retail so they sell not interested in the doctors added shares. Instys drop the price on current shares the retail sell and instys go from 26% ownership to 40% ownership in a couple of weeks. Just my thoughts. GL.
Presently, my vote is "No" to the increase, unless Anavex has more news. But, my other view is that there will be a significant release of data that turns my vote to "Yes."
I agree power. Nice post.
"Well talk on the street say you may go solo" A little fun for those of you that need to know. Couple shots of tequila. Via Tijuana
Great post, georgejjl. Thanks for your contribution's.
Interesting. My thoughts are Dr. Missling may have received a few calls over the past week with $40.00 $60.00 $80.00 dollar offers for the company and he was not interested.
So he raised more money just in case.
That's what a good CEO watch dog does.
Anavex - A2-73 Leader in the CNS biotech space. Stellar results and reviews to date. All the makings of a new block buster drug. Remember. No brain bleeding here. imo.
Company website posted on December 15th 2020.
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome.
https://www.anavex.com/anavex-life-sciences-announces-anavex2-73-blarcamesine-meets-primary-and-secondary-endpoints-in-placebo-controlled-u-s-phase-2-clinical-trial-for-the-treatment-of-adult-patients-with-rett-syn/
Exactamento! I have week Spanish. I was traveling when listening to this. Never looked at the final transcripts. June 7th was stuck in my head. Still, in review of that quarters report is very encouraging news for AVXL.
Also, That paragraph answers om questions discussed in the last couple days.
Steady_T - It was last quarters earnings call 2/11/21
This is what I thought was our meeting on June 7th. I work long hours.
Christopher Missling -- President and Chief Executive Officer
Obviously, I cannot predict what will happen on June 7th when the meeting from the FDA will take place to decide about Adu. But I would say that if it turns out positive, and that is a scenario you referred to, it would actually mean that the FDA would agree that one robust clinical study would be sufficient to approve a drug in Alzheimer's disease. And since we are running now a robust Phase 2b/3 study as well, this could be a positive for us in that regard. If the decision on the 7th of June is more negative in outcome, then it would still not, I believe will not in way or shape impaired because we are basically, by that time, advanced with our study and there's also ability for supportive data from the Phase 2a with our Phase 2b/3 study.
So we just put our heads down and move ahead, but I would think that it's possible that there will be positive resonance if the study would be approved -- the other study would be approved mid of the year.
https://www.fool.com/earnings/call-transcripts/2021/02/11/anavex-life-sciences-avxl-q1-2021-earnings-call-tr/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
T - I was traveling home on a Friday and had to make provisions to listen to the call. I'm pretty sure it was the February 19th call. He mentions that he has a scheduled meeting with the FDA about A2-73 on June 7th. That was the call when he said that three proven BP companies have dropped out of PD trials in the past year and we are still in it. It was also the call when he reviled our new cash of ( not sure how much ) 70 million enough operating capital for 3 years.
Possibly last quarters earnings report.
Hope this helps.
https://finance.yahoo.com/news/anavex-life-sciences-announces-participation-120000523.html
Steady_T - I thought Dr. Missling said in his last meeting that AVXL has a scheduled June 7th meeting date with the FDA. No?
I believe it was also mentioned that BIIB meets with the FDA on June 7th for aducanab or whatever its called.
More like see nothing, make something up. lol